Overview

Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer

Status:
Withdrawn
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to find out whether adding radiation therapy to the standard treatment of chemotherapy for prostate cancer is tolerated well and is more effective than the standard treatment of chemotherapy alone
Phase:
Phase 2
Details
Lead Sponsor:
Northwestern University
Collaborator:
Genzyme, a Sanofi Company
Treatments:
Docetaxel
Prednisone